Actively Recruiting
Pilot Study of Anti-CD19BCMA Universal CAR-T Cell Therapy for Adults With Relapsed or Resistant Autoimmune Diseases
Led by Changhai Hospital · Updated on 2026-02-25
60
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of anti-CD19BCMA U CAR T cells in patients with relapsed or refractory autoimmune diseases. This early phase 1, single-arm, open-label pilot study plans to enroll 60 patients to understand how this treatment works in conditions such as systemic lupus erythematosus, systemic sclerosis, primary Sjgren syndrome, rheumatoid arthritis, and anti-neutrophil cytoplasmic antibody-associated vasculitis. Participants will receive a dose-escalation treatment with anti-CD19BCMA CAR T cells called KN3601. Before the CAR T cell infusion, patients will be given Fludarabine and Cyclophosphamide on days -5, -4, and -3. The study will monitor the effects of a single-dose injection of these CAR T cells over a 52-week period following infusion. During the study, participants will be closely observed for dose-limiting toxicities and treatment-emergent adverse events up to 52 weeks after infusion. Researchers will also measure overall response rates, disease control rates, B cell depletion and recovery. Patients will undergo regular assessments and follow-ups throughout the study period to track safety and treatment impact, with the total observation lasting up to one year after treatment.
CONDITIONS
Brief Title
Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
Research Team
D
Dongbao Zhao
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here